Carl Dambkowski Sells 4,085 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) Stock

Apogee Therapeutics, Inc. (NASDAQ:APGE) insider Carl Dambkowski sold 4,085 shares of the business’s stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $46.94, for a total value of $191,749.90. Following the completion of the transaction, the insider now directly owns 255,348 shares of the company’s stock, valued at $11,986,035.12. The trade was a 1.57 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

Carl Dambkowski also recently made the following trade(s):

• On Wednesday, December 11th, Carl Dambkowski sold 4,540 shares of Apogee Therapeutics stock. The stock was sold at an average price of $48.76, for a total transaction of $221,370.40.
• On Wednesday, December 4th, Carl Dambkowski sold 6,665 shares of Apogee Therapeutics stock. The shares were sold at an average price of $46.07, for a total value of $307,056.55.
• On Wednesday, November 6th, Carl Dambkowski sold 6,665 shares of Apogee Therapeutics stock. The stock was sold at an average price of $59.12, for a total transaction of $394,034.80.

Apogee Therapeutics Stock Performance

Shares of APGE stock opened at $47.77 on Friday. The stock has a market capitalization of $2.15 billion, a P/E ratio of -19.74 and a beta of 2.30. Apogee Therapeutics, Inc. has a fifty-two week low of $27.05 and a fifty-two week high of $72.29. The company has a 50 day moving average price of $49.13 and a 200 day moving average price of $48.66.

Institutional Investors Weigh In On Apogee Therapeutics

Hedge funds have recently bought and sold shares of the stock. Wellington Management Group LLP grew its stake in shares of Apogee Therapeutics by 35.7% during the third quarter. Wellington Management Group LLP now owns 4,814,400 shares of the company’s stock worth $282,798,000 after purchasing an additional 1,267,451 shares in the last quarter. Driehaus Capital Management LLC increased its position in shares of Apogee Therapeutics by 2.6% during the second quarter. Driehaus Capital Management LLC now owns 2,117,870 shares of the company’s stock worth $83,338,000 after purchasing an additional 54,107 shares in the last quarter. Perceptive Advisors LLC boosted its stake in Apogee Therapeutics by 2.2% during the 2nd quarter. Perceptive Advisors LLC now owns 2,105,636 shares of the company’s stock worth $82,857,000 after purchasing an additional 45,241 shares during the period. Affinity Asset Advisors LLC lifted its position in Apogee Therapeutics by 41.2% during the 2nd quarter. Affinity Asset Advisors LLC now owns 836,283 shares of the company’s stock worth $32,908,000 after acquiring an additional 244,190 shares during the period. Finally, Geode Capital Management LLC lifted its holdings in shares of Apogee Therapeutics by 11.2% during the third quarter. Geode Capital Management LLC now owns 823,839 shares of the company’s stock worth $48,401,000 after purchasing an additional 82,978 shares during the period. Institutional investors and hedge funds own 79.04% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have commented on APGE. Canaccord Genuity Group started coverage on Apogee Therapeutics in a report on Monday, November 25th. They set a “buy” rating and a $89.00 target price for the company. Canaccord Genuity Group assumed coverage on shares of Apogee Therapeutics in a research note on Monday, November 25th. They issued a “buy” rating and a $89.00 price target on the stock. Guggenheim restated a “buy” rating on shares of Apogee Therapeutics in a research report on Thursday, December 12th. Finally, Wedbush upped their price objective on shares of Apogee Therapeutics from $87.00 to $90.00 and gave the company an “outperform” rating in a report on Monday, December 2nd. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $89.71.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.